PBYINasdaqPharmaceutical PreparationsFiscal year ends December 31

PUMA BIOTECHNOLOGY, INC.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026

$10.21+0.38 (+3.87%)

Close on Oct 19, 2026

Market cap: $537.01M
P/E (TTM): 19.6
Dividend yield: –

PUMA BIOTECHNOLOGY, INC. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31	FY 2010 2010-12-31	FY 2009 2009-12-31
Revenue	228	230	236	228	253	225	272	251	28	–	–	–	–	–	–	–	–
Cost of Revenue	58	64	63	55	64	39	37	35	5.57	–	–	–	–	–	–	–	–
Gross Profit	170	166	173	173	189	186	235	216	22	–	–	–	–	–	–	–	–
Research & Development	62	55	50	52	72	98	133	165	208	223	208	123	45	50	0.83	–	–
Selling, General & Admin	71	80	90	90	116	118	142	146	107	54	32	–	–	–	–	–	–
General & Administrative	–	–	–	–	–	–	–	–	–	54	32	19	9.79	25	9.33	–	–
Operating Expenses	–	–	–	–	–	256	311	346	320	277	240	142	55	74	10	–	–
Total Costs & Expenses	191	200	203	204	252	256	311	–	–	–	–	–	–	–	–	–	–
Operating Income	37	31	33	24	1.29	-30	-39	-95	-292	-277	-240	-142	-55	-74	-10	–	–
Interest Expense	6.62	12	13	12	13	14	15	11	0.72	–	–	–	–	–	–	–	–
Interest & Investment Income	4.08	4.72	2.61	0.81	0.16	0.49	2.85	1.80	1.26	0.96	0.97	0.32	0.17	0.10	0.00	–	–
Other Non-Operating Income	-1.52	-6.87	-9.97	-23	-30	-29	-36	-19	0.44	0.59	1.00	0.31	0.17	0.10	-0.08	–	–
Asset Impairment Charges	0	0	0.63	0	0	0	1.18	–	–	0	–	–	–	–	–	–	–
Gain (Loss) on Sale of Assets	0.00	0	0	0.00	0.00	0	-0.05	–	–	-0.37	–	–	–	–	–	–	–
Legal Settlements	–	0	0	-12	–	–	–	–	–	–	–	–	–	–	–	–	–
Pretax Income	36	24	23	0.46	-29	-60	-76	-114	–	–	–	–	–	–	–	–	–
Income Tax Expense	4.67	-6.18	1.08	0.46	0.32	0.21	0.05	0.02	0	0	0	0	0	0	–	–	–
Net Income incl. Noncontrolling Interests	–	–	–	–	–	-60	-76	-114	-292	-276	–	–	–	–	–	–	–
Net Income	31	30	22	0.00	-29	-60	-76	-114	-292	-276	-239	-142	-55	-74	-10	-0.02	-0.02
Net Income to Common	–	–	–	–	–	-60	-76	-114	-292	-276	-239	-142	-55	-74	-10	–	–
EPS (Basic)(per share)	0.62	0.62	0.46	0.00	-0.72	-1.52	-75,595.00	-2.99	-7.85	-8.29	-7.45	-4.73	-1.90	-3.42	-1.32	–	–
EPS (Diluted)(per share)	0.61	0.62	0.45	0.00	-0.72	-1.52	-1.95	-2.99	-7.85	-8.29	-7.45	-4.73	-1.90	-3.42	-1.32	–	–
Shares Outstanding (Basic, Weighted)(shares)	50	49	47	45	41	40	39	38	37	33	32	30	29	22	7.75	–	–
Shares Outstanding (Diluted, Weighted)(shares)	51	49	48	45	41	40	39	38	37	33	32	30	29	22	7.75	–	–
EBITDA	48	42	44	34	13	-20	-31	-87	-290	-275	-240	-142	-54	-74	-10	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 74.8%
Operating margin: 13.2%
Net margin: 11.6%
Return on equity, FY2025: 28.0%

Financial strength

Current ratio: 2.91
Debt to equity: 0.00
Debt to assets: 0.0%
Cash to current liabilities: 73.3%

Valuation

P/E ratio: 19.6
Price to sales: 2.32
Price to book: 3.88
Dividend yield: –